The PCCTC at GU ASCO 2023

This year’s ASCO GU Cancers Symposium, held 16-18 February in San Francisco, will featur...

The PCCTC’s IRONMAN Registry Receives Prestigious PCF Challenge Award

Principal Investigators Lorelei Mucci, ScD, MPH (Harvard T.H. Chan School of Public Health...

PCCTC Medical Director Michael Morris, MD Profiled, “A Triumph Against Prostate Cancer”

New technology provides a major step forward in diagnosing and treating prostate cancer.

JUST PUBLISHED—IRONMAN: A Novel International Registry of Men with Advanced Prostate Cancer

A new manuscript published in JCO Global Oncology describes the PCCTC managed IRONMAN Regi...

The PCCTC at ASCO22

More than 40,000 oncology professionals from around the world will convene at the annual A...

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

NORTH BILLERICA, MA, January 27, 2022 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus...

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

The Prostate Cancer Clinical Trials Consortium (PCCTC) Genetics Germline Working Group is ...

The PCCTC’s Guiding Principles

Towards achieving the ultimate goal of improving outcomes for patients, families, and care...

PCCTC trial is first to use standard Ra-223 doses, contemporary pain endpoints and PRO collection tools

First-of-its-Kind Study Looks at Link Between Genes and Prostate Cancer

Researchers from Johns Hopkins University, University of Washington School of Medicine see...

PCCTC Medical Director on the FDA Approval of Novel Prostate Cancer Imaging Tool

Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry

Bipolar Androgen Therapy for Patients Who Have Progressed on Abiraterone

Led by Dr. Samuel R. Denmeade and his team at Johns Hopkins School of Medicine – Sid...

PCCTC Germline Genetics Working Group Publishes New Guidelines

Practical considerations and challenges for germline genetic testing in patients with pros...

PCCTC Investigators on the Diversity of Enrollment in Prostate Cancer Clinical Trials

“Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Futu...

The Transformative Development and Progress of the PCCTC

Dr. Charles Ryan (University of Minnesota) is joined by the PCCTC’s CEO, Jake Vinson...

The PCCTC: Addressing Health Disparities by Increasing Diversity in Clinical Trials

A commitment to addressing prostate cancer health disparities.

Prostate Cancer Working Group 3 (PCWG3) Criteria in Clinical Trials

Dr. Alicia Morgans (Northwestern University Feinberg School of Medicine) welcomes PCCTC Me...

CellCentric signs agreement with the PCCTC for Phase II clinical trial expansion into the US

CCC19 Registry Launched to Understand COVID-19 in Patients with Cancer

All are encouraged to participate to quickly gather details related to patients with cance...

A Message Regarding COVID-19 from PCCTC CEO Jake Vinson

New York, NY (March 24, 2020) – In response to the ongoing COVID-19 pandemic, the PCCTC ...

Dr. Dana Rathkopf Discusses IRONMAN Registry with UroToday

IRONMAN – An International Registry for Men with Advanced Prostate Cancer.

PCCTC Investigators Author Key Paper on Liquid Biopsy Data

Effort organized by BloodPAC describes minimum technical data elements for liquid biopsy d...

Prostate Cancer ABCs Presents Patient and Caregiver Conference

Free event featuring PCCTC advocates Jan Manarite and Joel Nowak will take place Saturday,...

Metacure Trial: Can We Cure More Oligometastatic Prostate Cancer?

Study combines hormonal therapy with prostatectomy and radiation therapy of bone lesions

Phase I DSTP3086S Trial Results Published

PCCTC study demonstrates safety and antitumor activity of humanized immunoglobulin G1 anti...

PCCTC Investigators Drs. Rathkopf and McBride Receive Prestigious SU2C Grant

Award will fund novel trial using immunotherapy combined with radiation and hormone therap...

PCCTC Germline Genetics Working Group Publishes Results

Study published in Clinical Genitourinary Cancer argues multidisciplinary efforts are key ...

PCCTC Working Group Publishes Genetic Testing Manuscript

Investigators from the Prostate Cancer Clinical Trials Consortium (PCCTC) formed the Germl...

Phase III DORA Study Now Enrolling Patients with mCRPC

The phase III DORA study (ClinicalTrials.gov Identifier: NCT03574571) led by PCCTC investi...

Blood Test Predicts Resistance To Hormonal Therapy

AR-V7 successfully predicted resistance to hormonal therapy in advanced prostate cancer

Clinical Implications of Genetics in Prostate Cancer

PCCTC investigator Dr. Heather Cheng discusses future of cancer care.

The PCCTC Is Expanding

The PCCTC is currently seeking a Quality Manager and Clinical Data Manager to join its tea...

PCCTC Medical Director Discusses Biomarkers in Prostate Cancer

Dr. Michael Morris describes the need to be stratified by risk through biomarkers.

Movember Seeking Clinical Research Project Manager for IRONMAN Registry

The PCCTC serves as the the program’s Global Clinical and Data Coordination Center. ...

PCCTC Germline Genetics Working Group Publishes White Paper

Manuscript published in the Journal of Clinical Oncology – Precision Oncology discus...

Advocacy Symposium Led by PCCTC Investigator

Dr. Elisabeth Heath of Karmanos Cancer Institute will head up the 8th Annual Prostate Canc...

Blood Test Predicts Treatment Response, Survival in Metastatic Disease

PCCTC Scientific Oversight Committee Chair, Howard I. Scher, MD leads international study....

The PCCTC Is Expanding Its Trial Management Capabilities

To better meet the needs of our partners the PCCTC is expanding its infrastructure. Our ce...

IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer

PCCTC investigator Dr. Lorelei Mucci discusses innovative new registry initiative.

PCCTC-Developed Apalutamide Gains FDA Approval

On February 14, 2018, the Food and Drug Administration (FDA) approved the next-generation ...

PCCTC Muscadine (MPX) Study Finds Activity in Select Genotypes

A pre-planned subset analysis using a polymorphism of the superoxide dismutase-2 (SOD2) ge...

The PCCTC Salutes Its Very Own Angie Avery

Celebrating Veterans Week 2017, we salute Angie Avery, PCCTC Project Coordinator.

Timeline of PCCTC Clinical Contributions

The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP)...

Early Development Led by the PCCTC, FDA Approval Now Sought for Apalutamide

A new drug application (NDA) has been submitted to the FDA for apalutamide (ARN-509) for t...

7th Annual Prostate Cancer Advocacy Symposium: A National Summit in Detroit

The 7th Annual Prostate Cancer Advocacy Symposium: A National Summit in Detroit brings tog...

The PCCTC Selects Tempus as Sequencing and Analytics Provider for Phase II Clinical Trial

Tempus, a technology company focused on helping doctors personalize cancer care by collect...

Dr. Howard I. Scher on the Definition of Castration-Sensitive/Naive Prostate Cancer

The PCCTC’s Scientific Oversight Committee chair speaks with UroToday at the 2017 Ad...

PCCTC Trial Establishes Safety, Antitumor Activity of Apalutamide

Study represents a new standard that demonstrates the patient experience, useful for physi...

Dr. Lorelei Mucci Discusses Innovative IRONMAN Registry

IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cance...

Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity

PCCTC study serves as the foundation for a therapeutically relevant classification of pros...

PCCTC Trial Results: Neoadjuvant Enzalutamide Prior to Prostatectomy

Study led by the University of Washington published in Clinical Cancer Research provides e...

The PCCTC Is Seeking Talented Clinical Research Professionals

The PCCTC is currently seeking talented clinical research professionals to fill the positi...

Dr. Taplin, Leader in Novel Targeted Therapy Development

The Prostate Cancer Foundation (PCF) highlights the accomplishments of PCCTC investigator ...

Drs. Mucci and Kantoff on Outcomes Research and IRONMAN

Lorelei Mucci and Phil Kantoff, MD, discuss the PCCTC-managed International Registry to Im...

PCCTC’s Vital Role in Blood Profiling Atlas in Cancer (Blood PAC)

WASHINGTON, D.C. December 20, 2016 – The Breast Cancer Research Foundation (BCRF) and th...

PCCTC Leader Discusses Future of Liquid Biopsies in Prostate Cancer

Dr. Howard I. Scher, PCCTC Scientific Oversight Committee Chair, speaks on predicting sens...

Team PCCTC Joins Movember Effort

Prostate cancer is the second most common cancer in men worldwide. The PCCTC and Movember ...

The PCCTC to Advance VP Biden’s Cancer Moonshot Goals

PCCTC involved with new partnership in pursuit of creating an open database for liquid ...

ESMO 2016: PCCTC Study Benefits Men With Neuroendocrine Prostate Cancer

The selective aurora A kinase inhibitor Alisertib may benefit some patients with neuroend...

PCCTC Investigator Dr. Maha Hussain Develops Prostate Cancer Advances

Innovative physician-scientist exemplifies research excellence while maintaining strong co...

FDA-Designated Breakthrough Therapy Available in PCCTC Clinical Trial

The US Food and Drug Administration (FDA) recently granted Novartis’ CDK4/6 inhibitor LE...

PCCTC Facilitates Groundbreaking Prostate Cancer Gene Sequencing Study

Men with metastatic disease found more likely to harbor mutations in genes mediating DNA-r...

CDMRP Releases FY16 Clinical Consortium Research Site Award

The US Department of Defense (DoD) Prostate Cancer Research Program (PCRP), a division of...

PCCTC Collaborates with Florence Healthcare to Enhance Regulatory Document Management Capabilities

ATLANTA, GA and NEW YORK, June 10, 2016 – Florence Healthcare, developer of the innovati...

PCCTC Investigators Establish Guidelines for CRPC Clinical Trials

The latest recommendations from Prostate Cancer Working Group 3 (PCWG3) have already been...

VT-464, Drug in Development with PCCTC, Fast Tracked by FDA

Innocrin’s CYP17 lyase inhibitor seviteronel (VT-464), currently in PCCTC-led early ...

The PCCTC: Enabling the Practice of Precision Medicine

The Congressionally Directed Medical Research Programs (CDMRP) selects the PCCTC’s c...

The PCCTC and Movember: Supporting Prostate Cancer Research and Awareness.

Over 500 investigators, and research staff from PCCTC clinical research sites have come to...

Landmark Trial the First to Show the Benefit of Precision Medicine in Prostate Cancer

Oct. 28, 2015 — A major new trial, funded in part by the Prostate Cancer Foundation ...

WIRB-Copernicus Group and the PCCTC Announce New Partnership

PRINCETON, N.J. and NEW YORK, Sept. 29, 2015 /PRNewswire/ — WIRB-Copernicus Group® ...

Study led by PCCTC site describes prostate cancer’s genomic landscape

ANN ARBOR, Mich. — An international collaboration of researchers are advancing precision...

PCCTC Trial Demonstrates Longer Disease Control with Enzalutamide

SAN FRANCISCO, CA and TOKYO, JAPAN — (Marketwired) — 04/02/15 — Medivati...

Epic Sciences and The PCCTC Collaborate to Advance Therapeutic Development

SAN DIEGO – March 9, 2015 – Epic Sciences and The Prostate Cancer Clinical Trials Cons...

PCCTC Study Shows Zytiga May Improve Outcomes When Taken Before Prostatectomy

To address the need for better therapies for men with high-risk localized prostate cancer,...

Radium Ra 223 dichloride (Xofigo Injection) FDA Approved for Castration-Resistant Prostate Cancer (CRPC)

On May15, 2013, the U. S. Food and Drug Administration (FDA) approved radium Ra 223 dichlo...

RFA: PCCTC Affiliate Clinical Research Sites

The PCCTC is now accepting applications for its Affiliate Clinical Research Site program. ...

PCCTC Trial Shows Tasquinimod Prolongs Survival in Metastatic Prostate Cancer

Survival data from a phase II PCCTC trial of single agent tasquinimod (NCT00560482) furthe...

New Test Differentiates Low- and High-Risk Prostate Cancer

Genomic Health, Inc. announced the launch of its Oncotype DX® prostate cancer test whic...

FDA Approves Abiraterone acetate (Zytiga) For Second Indication

On December 10, 2012, the U. S. Food and Drug Administration (FDA) approved an expanded i...